New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates.
Resistance of Helicobacter pylori to clarithromycin occurs with a prevalence ranging from 0 to 15%. This has an important clinical impact on dual and triple therapies, in which clarithromycin seems to be the better choice to achieve H. pylori eradication. In order to evaluate the possibility of new mechanisms of clarithromycin resistance, a PCR assay that amplified a portion of 23S rRNA from H. pylori isolates was used. Gastric tissue biopsy specimens from 230 consecutive patients were cultured for H. pylori isolation. Eighty-six gastric biopsy specimens yielded H. pylori-positive results, and among these 12 isolates were clarithromycin resistant. The latter were studied to detect mutations in the 23S rRNA gene. Sequence analysis of the 1,143-bp PCR product (portion of the 23S rRNA gene) did not reveal mutation such as that described at position 2142 to 2143. On the contrary, our findings show, for seven isolates, a T-to-C transition at position 2717. This mutation conferred a low level of resistance, equivalent to the MIC for the isolates, selected using the E-test as well as using the agar dilution method: 1 micro g/ml. Moreover, T2717C transition is located in a highly conserved region of the 23S RNA associated with functional sites: domain VI. This fact has a strong effect on the secondary structure of the 23S RNA and on its interaction with macrolide. Mutation at position 2717 also generated an HhaI restriction site; therefore, restriction analysis of the PCR product also permits a rapid detection of resistant isolates.
Fontana
Carla
C
Department of Experimental Medicine and Biochemical Sciences, Tor Vergata University of Rome, Italy. fontanac@med.uniroma2.it
Favaro
Marco
M
Minelli
Silvia
S
Criscuolo
Anna Angela
AA
Pietroiusti
Antonio
A
Galante
Alberto
A
Favalli
Cartesio
C
D001483:Base Sequence; D017291:Clarithromycin / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial / Q000235:genetics*; D016480:Helicobacter pylori / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D012338:RNA, Ribosomal, 23S / Q000187:drug effects / Q000235:genetics*
D012338:RNA, Ribosomal, 23S; D017291:Clarithromycin